<DOC>
	<DOCNO>NCT02570854</DOCNO>
	<brief_summary>The study ass safety , tolerability efficacy CSJ137 chronic hemodialysis patient . It hypothesize treatment CSJ137 may improve level hemoglobin patient chronic hemodialysis iron-restricted anemia reduce need dose erythropoietin intravenous iron patient .</brief_summary>
	<brief_title>A Single-dose Study CSJ137 Anemic Chronic Hemodialysis Patients</brief_title>
	<detailed_description>This posting disclose information Part 1 CCSJ137X2201 . Another part , Part 2 , trial plan conduct subsequent initiation Part 1 different design Part 1 . The detail design additional part plan disclosure advance conduct Part 2 .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<criteria>1 . Hemodialysisdependent least 2 month prior screen . 2 . Receiving hemodialysis least 2 time per week 3 . Receiving chronic erythropoietin ( EPO ) therapy ; EPO dose increase 50 % 14 day prior baseline . 4 . Hemoglobin ( Hgb ) ≥ 8.5 &lt; 11.5 g/dL baseline . 5 . Ferritin &gt; 500 ng/mL ≤ 1000 ng/mL screen . 6 . TSAT ≤ 50 % minimum one time point 90 day prior baseline , TSAT ≤ 50 % baseline . 1 . Known diagnosis hemochromatosis , bone marrow malignancy , lymphatic malignancy myelodysplastic syndrome . 2 . History dialysis AV fistula thrombosis within 2 month prior screen , 2 episode AV fistula thrombosis within 6 month prior screen . 3 . Liver disease/dysfunction ( ChildPugh score ≥ 6 ) , prior liver transplant , heart failure ( NYHA Class III IV ) ; gastrointestinal bleeding . 4 . A positive Hepatitis B surface antigen test result . Patients Hepatitis C Virus ( HCV ) infection may include liver function eligibility criterion meet . 5 . ALT , AST bilirubin ≥ 1.5x ULN within 4 week prior baseline . 6 . Uncontrolled renal osteodystrophy define intact PTH ≥ 750 pg/mL screening . 7 . Conditions predispose increase risk serious infection , indwell vascular catheter ( central venous line hemodialysis catheter ) active infection require antibiotic therapy time 2 week prior screen . 8 . Blood transfusion administer within 4 week prior baseline . 9 . Cancer patient actively undergo chemotherapy screen receive chemotherapy within 3 month prior screen . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Anemia</keyword>
</DOC>